| Identification | Back Directory | [Name]
2,4-Thiazolidinedione, 5-[3-[3-(4-phenoxy-2-propylphenoxy)propoxy]phenyl]- | [CAS]
228577-00-2 | [Synonyms]
TZD18
TZD-18
TZD 18
2,4-Thiazolidinedione, 5-[3-[3-(4-phenoxy-2-propylphenoxy)propoxy]phenyl]- | [Molecular Formula]
C27H27NO5S | [MOL File]
228577-00-2.mol | [Molecular Weight]
477.57 |
| Hazard Information | Back Directory | [Description]
TZD18 is a novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. | [Uses]
TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 μM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes[1]. | [in vivo]
TZD18 (3, 10 mg/kg; p.o.; daily for 11 days) completes the correction of elevated plasma levels of both glucose and triglycerides in diabetic mice[1]. | Animal Model: | 12-13 weeks, Male db/db and nondiabetic db/+ (lean) mice (type 2 diabetes) [1] | | Dosage: | 3, 10 mg/kg | | Administration: | P.o.; daily for 11 days | | Result: | Reduced hyperglycemia and plasma triglyceride levels. |
| [IC 50]
hPPARα: 0.028 μM (IC50); hPPARγ: 0.057 μM (IC50); PPARδ: >10 μM (IC50) | [References]
[1] Guo Q, et al. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. DOI:10.1210/en.2003-1270 |
|
|